Last reviewed · How we verify

BP1001 in combination with LDAC

Bio-Path Holdings, Inc. · Phase 1 active Small molecule

BP1001 in combination with LDAC is a Small molecule drug developed by Bio-Path Holdings, Inc.. It is currently in Phase 1 development. Also known as: Liposomal Grb-2, L-Grb-2, BP-100-1.01, low dose ara-C.

At a glance

Generic nameBP1001 in combination with LDAC
Also known asLiposomal Grb-2, L-Grb-2, BP-100-1.01, low dose ara-C
SponsorBio-Path Holdings, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BP1001 in combination with LDAC

What is BP1001 in combination with LDAC?

BP1001 in combination with LDAC is a Small molecule drug developed by Bio-Path Holdings, Inc..

Who makes BP1001 in combination with LDAC?

BP1001 in combination with LDAC is developed by Bio-Path Holdings, Inc. (see full Bio-Path Holdings, Inc. pipeline at /company/bio-path-holdings-inc).

Is BP1001 in combination with LDAC also known as anything else?

BP1001 in combination with LDAC is also known as Liposomal Grb-2, L-Grb-2, BP-100-1.01, low dose ara-C.

What development phase is BP1001 in combination with LDAC in?

BP1001 in combination with LDAC is in Phase 1.

Related